EGFR and lung adenocarcinoma: EGFR T790M mutation is the most prevalent mechanism of acquired resistance in lung adenocarcinoma patients with EGFR sensitive mutation who have been treated with first‐ or second‐generation EGFR‐TKIs as their initial therapy, accounting for nearly 50%–60% [5, 6, 7].